The unexpected impact of a Chlamydia trachomatis infection control program on susceptibility to reinfection.
about
Intravaginal Chlamydia trachomatis Challenge Infection Elicits TH1 and TH17 Immune Responses in Mice That Promote Pathogen Clearance and Genital Tract DamageCollateral Damage: Detrimental Effect of Antibiotics on the Development of Protective Immune MemoryA vaccine formulated with the major outer membrane protein can protect C3H/HeN, a highly susceptible strain of mice, from a Chlamydia muridarum genital challengeMultiple Chlamydiaceae species in trachoma: implications for disease pathogenesis and controlA 3-dimensional trimeric β-barrel model for Chlamydia MOMP contains conserved and novel elements of Gram-negative bacterial porinsScreening programmes for chlamydial infection: when will we ever learn?Possible changes in the transmissibility of trachoma following MDA and transmission reduction: implications for the GET2020 goals.A rationale for continuing mass antibiotic distributions for trachomaA discrepancy of Chlamydia trachomatis incidence and prevalence trends in Finland 1983-2003.Immunobiological outcomes of repeated chlamydial infection from two models of within-host population dynamics.Current crisis or artifact of surveillance: insights into rebound chlamydia rates from dynamic modelling.Increased immunoaccessibility of MOMP epitopes in a vaccine formulated with amphipols may account for the very robust protection elicited against a vaginal challenge with Chlamydia muridarum.Behavioural sources of repeat Chlamydia trachomatis infections: importance of different sex partners.Chlamydia muridarum T-cell antigens formulated with the adjuvant DDA/TDB induce immunity against infection that correlates with a high frequency of gamma interferon (IFN-gamma)/tumor necrosis factor alpha and IFN-gamma/interleukin-17 double-positiveChlamydia trachomatis strains and virulence: rethinking links to infection prevalence and disease severityWhole genome identification of C. trachomatis immunodominant antigens after genital tract infections and effect of antibiotic treatment of pigtailed macaques.Chlamydia trachomatis control requires a vaccine.Evaluation of a multisubunit recombinant polymorphic membrane protein and major outer membrane protein T cell vaccine against Chlamydia muridarum genital infection in three strains of mice.Maternal immunity partially protects newborn mice against a Chlamydia trachomatis intranasal challengeDeterminants of sexual network structure and their impact on cumulative network measures.Enhancement of the protective efficacy of a Chlamydia trachomatis recombinant vaccine by combining systemic and mucosal routes for immunization.Protective immunity to Chlamydia trachomatis genital infection: evidence from human studies.Inhibitory effects of 405 nm irradiation on Chlamydia trachomatis growth and characterization of the ensuing inflammatory response in HeLa cellsChlamydia trachomatis polymorphic membrane protein D is a species-common pan-neutralizing antigenInterruption of CXCL13-CXCR5 axis increases upper genital tract pathology and activation of NKT cells following chlamydial genital infection.Individual and population level effects of partner notification for Chlamydia trachomatis.Recent advances in understanding and managing Chlamydia trachomatis infections.Chlamydia public health programs and the epidemiology of pelvic inflammatory disease and ectopic pregnancy.Development of a Chlamydia trachomatis T cell Vaccine.Perforin is detrimental to controlling [corrected] C. muridarum replication in vitro, but not in vivo.The role of reinfection and partner notification in the efficacy of Chlamydia screening programsImmunization with live and dead Chlamydia muridarum induces different levels of protective immunity in a murine genital tract model: correlation with MHC class II peptide presentation and multifunctional Th1 cells.Chlamydia-specific CD4 T cell clones control Chlamydia muridarum replication in epithelial cells by nitric oxide-dependent and -independent mechanisms.Assessment of transmission in trachoma programs over time suggests no short-term loss of immunity.Immunogenicity of a vaccine formulated with the Chlamydia trachomatis serovar F, native major outer membrane protein in a nonhuman primate modelManagement of Chlamydia trachomatis genital tract infection: screening and treatment challenges.A TLR2 agonist is a more effective adjuvant for a Chlamydia major outer membrane protein vaccine than ligands to other TLR and NOD receptors.Chlamydia trachomatis load in population-based screening and STI-clinics: implications for screening policy.Current concepts in bacterial sexually transmitted diseases.Sexually transmitted infections in Canada: A sticky situation.
P2860
Q27323271-2FE9BCF7-4DB6-4491-9A53-1FFC44BC26FEQ28066947-E3527017-1730-45EF-8918-0B26CE277F9BQ28391567-29502590-9187-4790-8686-4328C0C441C1Q28471929-89CB7522-2259-4482-9F32-0C57ECE04F8DQ30153534-DD9CE575-E0FA-49CA-9563-8E5AB4684453Q30479244-C5DF0F5E-A27C-4B11-AB1C-8B5D22C8F0AAQ30670495-A7F30BCB-87DB-4AD1-A4A8-AEA76D018BC2Q33293477-D9FB88B6-D90F-46A1-82C6-01F4E5A70916Q33394372-615DB6C7-EBC7-4DA9-9785-9468279AD4DBQ33499684-FCB5EF3C-4E2B-49E6-8825-C6AE049980BAQ33541279-A0D19204-3002-4CF8-A7B5-2B0113BAA56DQ33648677-AE4196A9-5106-4D83-AACD-6AA75A46E278Q33707958-B8247E45-B22C-489E-B0FA-FD708D848493Q33826107-EE729739-7980-4FC9-BD69-E9A9E229B311Q33885417-5A70A233-4FE3-431E-A579-7BB2B5D58001Q33957971-C4E2C14B-22D5-4269-A724-3B80F3613A1AQ34103774-BC170B1B-BAF6-45DB-B9AD-E8AFC7B8F5C3Q34103785-E850044D-FD07-4845-8DA8-23965861185EQ34172833-6A04FAAA-894E-4E10-8739-99504AC7F9F1Q34262970-BBAD6402-CB58-456B-B149-BA95609DB2FAQ34311438-1185DC74-750E-4BA0-B0F5-31277940D6B0Q34345929-7D3726A1-41C3-4581-8834-A0C7EB880317Q34380815-F5071A8A-9B6D-41BB-A688-EBA225D20281Q34478609-BAD14882-77BB-4952-B7D6-24DC19E6870AQ34493665-E7D60CF2-E2F3-4FC1-8FD9-F2D8565680A8Q34516651-E21D728A-BCAA-499B-B647-A7C2F3C90686Q34608855-E871F8FA-0A05-4B9E-95BA-46767CABEA35Q34644581-B7385FFF-E087-4049-A738-4B2A6B3DF9C6Q34663987-AE53CEAB-A7D4-481D-B16F-D3D9CB2C0E78Q34730267-7B12047A-5531-4E05-B929-73415DF85F2FQ34763875-284DDA83-6043-41D8-A306-2AF4A46EAD70Q34773772-61160600-E71F-4C4E-BA71-44478EAF9723Q34774853-B74EF6B4-0D46-4A28-AED9-B5400862310BQ34855220-5A0BAFFD-28AE-4515-A068-1F1AAA04F163Q34886221-7C1E9278-7574-4225-8398-A754CE4C8156Q35026625-93252D08-CAD3-440B-B77E-4F7E9E0F71C6Q35166960-DB653131-0CC6-4F1A-A9F2-A7DC471733F1Q35235300-761303D9-D5BF-45D3-A595-33AE26800F14Q35407397-96EB39A0-4711-4040-8489-75276722F6F9Q35433936-F09DC045-0EFF-4A0C-8C9D-45988EDEC568
P2860
The unexpected impact of a Chlamydia trachomatis infection control program on susceptibility to reinfection.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 10 October 2005
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The unexpected impact of a Chl ...... susceptibility to reinfection.
@en
The unexpected impact of a Chl ...... susceptibility to reinfection.
@nl
type
label
The unexpected impact of a Chl ...... susceptibility to reinfection.
@en
The unexpected impact of a Chl ...... susceptibility to reinfection.
@nl
prefLabel
The unexpected impact of a Chl ...... susceptibility to reinfection.
@en
The unexpected impact of a Chl ...... susceptibility to reinfection.
@nl
P2093
P356
P1476
The unexpected impact of a Chl ...... susceptibility to reinfection.
@en
P2093
Babak Pourbohloul
Michael L Rekart
Rick White
Robert C Brunham
P304
P356
10.1086/497341
P407
P50
P577
2005-10-10T00:00:00Z